NR4A1 and breast carcinoma: Specifically, hormone-receptor-positive (HR+) breast cancer (BC) makes up approximately 60% to 75% of breast cancer patients, and the five-year survival rate of stage IV ER+/PR+ breast cancer patients is below 20% [4,5].